Abstract
Background Zellweger Spectrum Disorder (ZSD) is caused by bi-allelic defects in any of 13 PEX genes, resulting in failure to form functional peroxisomes. Individuals manifest a wide spectrum of clinical phenotypes and severity, but almost all have retinal degeneration leading to blindness. The onset, extent and progression of retinal findings has not been well-described and there are no therapies for treating vision loss. With expanding research and trials on retinal gene therapy for genetic disorders, it is now crucial to understand the natural history of vision loss in ZSD for defining reliable endpoints for upcoming interventional trials.
Here we describe ophthalmic findings in the largest number of ZSD patients to date.
Methods We reviewed ophthalmology records from our retrospective longitudinal cohort of 66 patients, and cross-sectional ophthalmic findings from 79 patients reported in the literature. We divided patients by severe, intermediate or mild disease based on genotypes or their reported disease severity.
Results We found that visual acuity (VA) declines slowly (+0.01 Logmar/year) with a mean of 0.93 Logmar (0 = normal vision, 1 = legal blindness) in all 53 intermediate-mild patients with available data. Longitudinal VA data revealed slow loss over time and legal blindness onset at average age 7.8 years. Fundoscopy showed retinal pigmentation, macular abnormalities, small or pale optic discs and attenuated vessels with higher prevalence in milder severity groups and did not change with age. Electroretinogram (ERG) tracings were diminished in 93% of patients, 40% of which were extinguished. ERG responses did not change over time in patients with multiple ERGs. Optical coherence tomography (OCT), reported only in milder patients, revealed cystoid macular edema or macular schisis in 16/21 (age 1.8-30 years). Serial OCTs showed evolution or stable macular edema.
Conclusions Although limited by retrospective data, we highlight several useful conclusions (1) VA slowly deteriorates and is without clear association with disease severity, (2) serial ERGs are not useful for documenting vision loss progression and (3) intraretinal cysts may be common in ZSD. This study indicates that systematically reporting multiple measures will be required for accurately assessing visual function in the ZSD population, including measures of functional vision.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was done as part of our Natural History Study on Peroxisomal Disorders (NCT01668186) and was funded by the Canadian Institutes of Health Research (CIHR) (Grant # 126108) to NEB and academic salary grant from Travere TherapeuticsTM to NEB for the clinical research coordinator of the study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Review Ethics Board of the McGill University Health Center gave ethical approval for this work (Study #11-090-PED). Participants or their legal representatives provided their consent to be part of the Natural History study #11-090-PED and to have the results of this study published. Participants or their legal representative provided their authorizations for obtaining their medical records for this study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
